Phase 3 Clinical Trials With Primary Completion Dates in November 2016

This is a list of Phase 3 trials with primary completion dates in November 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AERIAerie Pharmaceuticals, Inc.2016-11-01Phase 3NCT02558374Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
CBPOChina Biologic Products, Inc.2016-11-01Phase 3NCT02623556Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
CLDXCelldex Therapeutics, Inc.2016-11-01Phase 3NCT01480479Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
FGENFibroGen, Inc2016-11-01Phase 3NCT02652806FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
HZNPHorizon Pharma plc2016-11-01Phase 3NCT02415127Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
MMSIMerit Medical Systems, Inc.2016-11-01Phase 3NCT02159898EndoMAXX EVT Compared to EndoMAXX
NWBONorthwest Biotherapeutics, Inc.2016-11-01Phase 3NCT00045968Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
ONTXOnconova Therapeutics, Inc.2016-11-01Phase 3NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
OTICOtonomy, Inc.2016-11-01Phase 3NCT02801370Phase 3 Study of OTO-201 in Acute Otitis Externa
PCRXPacira Pharmaceuticals, Inc.2016-11-01Phase 3NCT02713230Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
PCRXPacira Pharmaceuticals, Inc.2016-11-01Phase 3NCT02713178Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty
PTCTPTC Therapeutics, Inc.2016-11-01Phase 3NCT02139306Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
REPHRecro Pharma, Inc.2016-11-01Phase 3NCT02678286Evaluation of N1539 Following Abdominoplasty Surgery
RPTPRaptor Pharmaceutical Corp.2016-11-01Phase 3NCT01744782Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
TAROTaro Pharmaceutical Industries Ltd.2016-11-01Phase 3NCT02933866Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis